The 20-month retrospective cohort study looked at infection rates experienced by 209 patients with recognized risk factors for infection whose cardiac implantable electronic device procedures included use of the implanted AIGISRx Envelope. These infection rates were compared with the infection rates experienced by a control cohort of 671 patients with matched risk factors.
The researchers found no CIED infections in patients who received AIGISRx implants after 90 days, compared to 15 infections in the control group.
Learn more about TYRX.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
